Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy

NCT03177083 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsing Remitting Multiple Sclerosis

Interventions

DRUG: peginterferon beta-1a
DRUG: interferon beta-1a
DRUG: interferon beta-1b

Sponsor

Biogen